Everything We Know About BioCryst's New HAE Drug
BioCryst's Hereditary angioedema drug-trial results not compelling.
Hereditary angioedema, or HAE, is a rare genetic blood disorder that causes potentially life-threatening swelling in various body parts. Current treatments used to reduce and prevent swelling are fairly effective, but require injections. BioCryst's (BCRX) - Get Report once-daily pill BCX7353 could offer a more convenient treatment, but investors await trial results that are more comparable to the inject-able drugs Shire (SHPG) - Get Report has in development.
READ THE FULL STORY HERE: BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns
This article was written by a staff member of TheStreet.
